

Contact Person: Phyllis D. Artis, Grant Technical Assistant, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-6470.

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers 93.126, Small Business Innovation Research; 93.176, ADAMHA Small Instrumentation Program Grants; 93.242, Mental Health Research Grants; 93.281, Mental Research Scientist Development Award and Research Scientist Development Award for Clinicians; 93.282, Mental Health Research Service Awards for Research Training; and 93.921, ADAMHA Science Education Partnership Award.)

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-11420 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Oncoimmunins

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I) that the National Institutes of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in a U.S. Patent 5,364,619 and U.S. Patent Applications; USSN 07/764,695 and USSN 08/218,023 and corresponding foreign patent applications each entitled, "Oncoimmunins" to Oncoimmunin, Inc. of Kensington, Maryland. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Tumor-infiltrating lymphocytes (TILs) have shown in vivo antitumor efficacy in both animal and human studies. Functions thought necessary for antitumor activity include cytolysis, homing, and proliferation at tumor sites. T-cell mitogens of tumor origin have been suggested to be responsible, in part, for the local stimulation of T-lymphocytes around tumors. Two tumor-derived, soluble proteins named Oncoimmunin-L and Oncoimmunin-M have been isolated and partially characterized. Oncoimmunin-L is a T-cell mitogen and Oncoimmunin-M is a myeloid differentiation inducing agent. The partial characterization of these two factors has shown that they are similar to human leukocyte elastase inhibitor and human lactate dehydrogenase M, respectively. As cells of both lymphoid and myeloid origin are known to play roles in immune defense, factors which can modulate their number and/or function may be useful in the diagnosis and treatment of cancer. Since these factors are derived from tumors, their appearance in blood may signal the presence of tumor or of metastatic disease. The in vivo bioactivities of these factors suggests their utility as therapeutic agents for cancer and infectious diseases.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Raphe Kantor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in any field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or before July 10, 1995 will be considered.

Dated: April 24, 1995.

Maria C. Freire,

Director, Office of Technology Transfer.

[FR Doc. 95-11423 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-P

Prospective Grant of Exclusive License: Neuro-Derived Fetal Cell Lines for Transplantation Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent 4,707,448, entitled "Immortal Line of Human Fetal Glial Cells," U.S. Patent Application SN 08/046,527 entitled "Use of Neuro-Derived Fetal Cell Line for Transplantation Therapy" and corresponding foreign patent applications to Pro-Virus, Inc. of Rockville, Maryland. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent discloses a novel immortalized fetal glial cell line, designated SVG. The pending patent application discloses the methods of using such cell lines or genetically modified clones thereof for therapeutic purposes to treat various neurological diseases and disorders via transplantation of the cell lines into the patient. Cell lines, such as SVG, have the advantage of being a continually renewable resource and relatively homogenous. Additionally, such cell lines eliminate the significant safety concerns associated with primary human fetal tissue transplants that may harbor opportunistic disease-causing agents and may be subjected to a battery of tests to ensure their safety and efficacy before being used in transplantation.

ADDRESSES: Requests for copies of the patent and the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Mr. Arthur J. Cohn, Esq., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20892-3804. Telephone: (301) 496-7735 ext 284; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated